Диссертация (1174220), страница 46
Текст из файла (страница 46)
– 2009. – 132. - Р. 250-259.270. Ostojic S., Stevanovic D., Jancic J. Quality of life and its correlates in adolescent multiplesclerosis patients. // Mult Scler Relat Disord. – 2016. – 10. - Р. 57-62.271. Pakdaman H., Amini Harandi A., Gharagozli K., Health-related quality of life in patients withrelapsing-remitting multiple sclerosis treated with subcutaneous interferon β-1a in Iran. // Int JNeurosci. – 2017.
- 127(6). - Р. 501-507.272. Pan G., Simpson S.Jr., van der Mei I., et al. Role of genetic susceptibility variants in predictingclinical course in multiple sclerosis: a cohort study. // J Neurol Neurosurg Psychiatry. – 2016. 87(11). - Р. 1204-1211.273. Parkin D., Jacoby A., McNamee P. Treatment of multiple sclerosis with interferon beta –1b: Anappraisal of cost-effectiveness and quality of life. // J Neurol Neurosurg Psych. – 2000. – 68. - Р.144 –149.274.
Patti F., Amato M.P., Battaglia M.A. et al. Caregiver quality of life in multiple sclerosis: amulticentre Italian study. // Mult Scler. – 2007. – 13. - Р. 412–419.275. Patti F., Pozzilli C., Montanari E. et al. Effects of education level and employment status onHRQoL in early relapsing-remitting multiple sclerosis. // Mult Scler. - 2007a. - 13(6). - Р. 783791.191276. Patti F., Russo P, Pappalardo A., et al. Predictors of quality of life among patients with multiplesclerosis: an Italian cross-sectional study. // J Neurol Sci. - 2007b. - 252(2). - Р.
121-129.277. Paty D.W., Li D.K., UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.MRI analysis results of a multicenter, randomized, doubleblind, placebo- Interferon beta-1b iseffective in relapsing-remitting multiple sclerosis: II: controlled trial. // Neurology. – 1993. 43(4). - Р. 662-667.278. Pekmezovic T., KisicTepavcevic D., Kostic J., Drulovic J.
Validation and cross-culturaladaptation of the disease-specific questionnaire MSQOL-54 in Serbian multiple sclerosispatients sample. // Quality of Life Research. – 2007. - 16(8). - Р. 1383–1387.279. Penner I.K., Bechtel N, Raselli C, et al. Fatigue in multiple sclerosis: relation to depression,physical impairment, personality and action control. // Mult Scler. – 2007. - 13(9). - Р. 11611167.280. Perneger T.V., Leplеge A., Etter J.F., Rougemont A. Validation of a French-language version ofthe MOS 36-Item Short Form Health Survey (SF-36) in young healthy adults. // J ClinEpidemiol. – 1995. - 48(8). - Р.
1051-1060.281. Pfaffenberger N., Pfeiffer K.P., Deibl M., et al. Association of factors influencing health-relatedquality of life in MS. // Acta Neur Scand. – 2006. - 114(2). - Р. 102–108282. Pittion-Vouyovitch S., Debouverie M., Guillemin F. et al. Fatigue in multiple sclerosis is relatedto disability, depression and quality of life.
// J Neurol Sci - 2006. - 243(1-2). - Р. 39–45.283. Pittock S.J., Mayr W.T., McClelland R.L. at el. Quality of life is favorable for most patients withmultiple sclerosis: a population-based cohort study. // Arch Neurol. – 2004. - 61(5). - Р. 679-686.284. Planche V., Moisset X., Morello R.
et al. Improvement of quality of life and its relationship withneuropsychiatric outcomes in patients with multiple sclerosis starting treatment withnatalizumab: A 3-year follow-up multicentric study. // J Neurol Sci. – 2017. – 382. - Р. 148-154.285. Plavina T., Subramanyam M., Bloomgren G. et al. Anti-JC virus antibody levels in serum orplasmafurtherdefineriskofnatalizumab-associatedprogressivemultifocalleukoencephalopathy. // Ann Neurol. – 2014. – 76. - Р. 802–812.286.
Polman C., O‘Connor P., Havrdova E., et al. A randomized, placebo-controlled trial ofnatalizumab for relapsing multiple sclerosis. // N Engl J Med. – 2006. – 354. - Р. 899–910.287. Polman C.H., Reingold S.C., Edan G. et al. Diagnostic Criteria for Multiple Sclerosis: 2005Revisions to the ―McDonald Criteria‖. // Ann Neurol. – 2005. -58. - Р. 840-846.288. Polman C.H., Reingold S.C., Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010revisions to the McDonald criteria. // Ann Neurol.
– 2011. - 69(2). - Р. 292-302.192289. Portaccio E., Zipoli V., Goretti B. et al. ApolipoproteinE epsilon 4 allele is not associated withdisease course and severity in multiple sclerosis. // Acta Neurol Scand. – 2009. – 120. - Р. 439441.290. Poser C.M.., Paty D.W., Scheinberg L. et al. New diagnostic criteria for multiple sclerosis:guidellines for research protocols. //Ann Neurol. – 1983. – 13. - Р. 227-231.291. Poser S., Poser W., Schlaf G. et al.
Prognostic indicators in multiple sclerosis. // Acta NeurolScand. – 1986. -74. - Р. 387-392.292. Pravatà E., Rocca M.A., Valsasina P., Riccitell G.C. Gray matter trophism, cognitiveimpairment, and depression in patients with multiple sclerosis. // Mult Scler. – 2017. - 23(14). Р. 1864–1874.293. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously inMultiple Sclerosis) Study Group.
Randomised doubleblind placebo-controlled study ofinterferon beta-1a in relapsing/remitting multiple sclerosis. // Lancet. – 1998. - 352(9139). - Р.1498-1504.294. Quarto G., Autorino R., Gallo A. et al. Quality of life in women with multiple sclerosis andoveractive bladder syndrome. // Int Urogynecol J Pelvic Floor Dysfunct.
– 2007. - 18(2). - 189194.295. Radick L. & Mehr S.R. The latest innovations in the drug pipeline for multiple sclerosis. // AmHealth Drug Benefits. – 2015. – 8. - Р. 448–453.296. Riaz I.A., Hobart J., Lamping D. et al. Multiple Sclerosis Impact Scale (MSIS-29): reliabilityand validity in hospital-based samples.
// J Neurol Neurosurg Psychiatry. – 2002. - 73(6). - Р.701–704.297. Rice D.P. Cost of illness studies: What is good aboutthem? // Inj Prev. – 2000. – 6. - Р. 177–179.298. Rice G.P., Oger J., Duquette P. et al. Treatment with interferon beta-1b improves quality of lifein multiple sclerosis. // Neurol Sci.
– 1999. - 26 (4). - Р. 276–282.299. Riduck R.A., Miller D., Hass S. et al. Health-related quality of life in multiple sclerosis: effectsof natalizumab. // Ann Neurol. – 2007. – 62. - Р. 335–346.300. Rivas-Rodríguez E., Amezcua L. Ethnic Considerations and Multiple Sclerosis DiseaseVariability in the United States. // Neurol Clin. – 2018. - 36(1). - Р. 151-162.301.
Rudick R.A., Stuart W.H., Calabresi P.A. et al; SENTINEL Investigators. Natalizumab plusinterferon beta-1a for relapsing multiple sclerosis. // N Engl J Med. – 2006. – 354. - Р. 911-923.302. Sadovnick A. D., Yee., I. M, Guimond C. et al. Age of onset in concordant twins and otherrelative pairs with multiple sclerosis. // Am. J.
Epidemiol. -2009. – 170.- Р. 289–296.303. Sahraian M.A., Sahebkar M., Dehghani R. et al. Multiple sclerosis-A disease on a dramaticallyrising trend in Iran: Review of possible reasons. // Iran J Neurol. – 2017. - 16(1).- Р. 34-40.193304. Saul A., Ponsonby A.L., Lucas R.M. et al.
Stressful life events and the risk of initial centralnervous system demyelination. // Mult Scler. – 2017. - 23(7). - Р. 1000-1007.305. Scannevin R., Chollate S., Jung M. et al. Fumarates promote cytoprotection of the centralnervous system against oxidative stress via the nuclear factor (erythroid-derived 2)-like pathway.// J Pharmacol Exp Ther. – 2012. – 341. - Р. 274–284.306. Schumacher G.A., Beebe G., Kibler R.f. et al. Problems of experimental trials of therapy inmultiple sclerosis - report by the Panel on the Evaluation of Experimental Trials of Therapy inMultiple Sclerosis.
// Ann NY Acad Sci. -1965. – 122. - Р. 552-568.307. Schwartz C.E., Coulthard-Morris L., Cole B., Vollmer T. The quality-of-life effects of interferonbeta-1b in multiple sclerosis. // Arch Neurol. – 1997. – 54. - Р. 1475–1480.308. Shi J., Zhao C.B., Vollmer T.L. et al. APOE epsilon 4 allele is associated with cognitiveimpairment in patients with multiple sclerosis. // Neurology. – 2008.
– 70. - Р. 185-190.309. Simeoni M.C., Auquier P., Fernandez O. et al. Validation of the multiple sclerosis internationalquality of life questionnaire. // Multiple Sсlerosis. – 2008. – 14. - Р. 219-230.310. Simon K.C., van der Mei I.A., Munger K.L. et al. Combined effects of smoking, anti-EBNAantibodies, and HLA-DRB1*1501 on multiple sclerosis risk. // Neurology. – 2010. – 74. - Р.1365-71.311. Simone I.L., Ceccarelli A., Tortorella C. et al. Influence of Interferon beta treatment on qualityof life in multiple sclerosis patients. // Health Qual Life Outcomes. – 2006.
- 4:- Р. 96.312. Singer B.A. The role of natalizumab in the treatment of multiple sclerosis: benefits and risks. //Ther Adv Neurol Disord. – 2017. - 10(9). - Р. 327-336.313. Sitthipornvorakul E., Klinsophon T., Sihawong R., Janwantanakul P. The effects of walkingintervention in patients with chronic low back pain: A meta-analysis of randomized controlledtrials.
// Musculoskelet Sci Pract. – 2017. – 34. - Р. 38-46.314. Soerensen P.S. New management algorithms in multiple sclerosis. // Curr Opin Neurol. – 2014. 27(3). - Р. 246–259.315. Sombekke M.H., Lukas C., Crusius J.B. et al. HLA-DRB1*1501 and spinal cord magneticresonance imaging lesions in multiple sclerosis.
// Arch. Neurol. – 2009. – 66. - Р. 1531-1536.316. Strautins K., Tschochner M., James I. et al. Combining HLA-DR risk alleles and anti-EpsteinBarr virus antibody profiles to stratify multiple sclerosis risk. // Mult Scler. – 2014. - 20(3). - Р.286-294.317. Stys P.K., Zamponi G.W., Van M.J. et al. Will the real multiple sclerosis please stand up? // NatRev Neurosci. – 2012. – 13. - Р. 507–514.318. Sullivan M.J., Weinshenker B. et al.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
